Search research articles
Contact Us
Filters
Showing results (121-130 of 148) with videos related to
Page
of 15
Sort By:
American Journal of Hematology
|
January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Yazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
American Journal of Hematology
|
December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival
Omer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
Nature Communications
|
November 9, 2019
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia
Liping Dou, Fei Yan, Jiuxia Pang, et al.
Blood Neoplasia
|
March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial
James M Foran, Zhuoxin Sun, Selina M Luger, et al.
American Journal of Hematology
|
December 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Naseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
Blood Advances
|
April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Mayo Clinic Proceedings
|
June 6, 2018
Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information
Ayalew Tefferi, Naseema Gangat, Mythri Mudireddy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Cancer Journal
|
April 6, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
Saubia Fathima, Lior Rokach, Nour Ghosoun, et al.
Blood Cancer Journal
|
June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma
Binoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 148) with videos related to
Sort By:
Page
of 15
American Journal of Hematology
|
January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Yazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
American Journal of Hematology
|
December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival
Omer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
Nature Communications
|
November 9, 2019
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia
Liping Dou, Fei Yan, Jiuxia Pang, et al.
Blood Neoplasia
|
March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial
James M Foran, Zhuoxin Sun, Selina M Luger, et al.
American Journal of Hematology
|
December 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Naseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
Blood Advances
|
April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Mayo Clinic Proceedings
|
June 6, 2018
Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information
Ayalew Tefferi, Naseema Gangat, Mythri Mudireddy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Cancer Journal
|
April 6, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
Saubia Fathima, Lior Rokach, Nour Ghosoun, et al.
Blood Cancer Journal
|
June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma
Binoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Page
of 15